Tomorrow! Registration is still open! Time-tested gout therapies remain the cornerstone of care, optimizing their use requires thoughtful, patient-specific decision making. Join our expert faculty for Upgrading & Maximizing the Classics where they'll explore practical https://t.co/ZN0vcVjUex

Gout TRUST trial compared gout flares in 28 pts assessed biweekly electronically or by phone. Over 12 wk (109 flare periods, 108 electronic & 99 phone assessments) there were 23 flares on electronic surveys and 22 flares on phone surveys (96% agreement; strong concordance, ICC https://t.co/fugYIasf4G

True or False: Over 20 years in systemic sclerosis patients, steroid use increased from 18% to 50%. Did you get it right? See for yourself in this week's RheumIQ quiz at https://t.co/LATb1P18Sh https://t.co/8go6FkwOE0

🔁 Before their upcoming episode, revisit the 2025 conversation between Dr. Christina Charles-Schoeman and Dr. Manish Jain on timely treatment change after TNFi failure in RA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/vbc9RRkpwi https://t.co/pwYsRogOJx

Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf https://t.co/dTFjD4iqth

Metanalysis of 31 studies (14,548 pts) looked at infection in idiopathic inflamm myopathy (IIMs). Infection prevalence was 24%, primarily Respiratory tract. PJP, aspergillosis, H zoster most prevalent pathogens. Risk factors: older age, male, DM, HTN,MDA5+ (OR 3.41), rapidly https://t.co/GvOvAVRkRv

RheumIQ: True or False: In an international consortium of RA patients, MACE risk was significantly associated with disease activity but not ACPA positivity. Test your knowledge here: https://t.co/LATb1P18Sh https://t.co/Bs1ReJk0OY

CAR-T Therapy: EULAR 2026 Conference Recap https://t.co/3CUp5MTN2Y https://t.co/agk5HNUSwg

In the 60-120 days following an acute gout flare, the risk of MI nearly doubles, and the risk of stroke rises significantly. For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/263CS1obPf

Optimize the therapies you use every day. Join leading gout experts as they discuss practical strategies for treat-to-target, adherence, and managing complex Gout patients. Drs: Ted Mikuls, Michael Pillinger, and Lisa Stamp Moderated by: Dr. Jack Cush Gain practical insights https://t.co/47NoiPR6GG

Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease. Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz #CARTCellTherapy https://t.co/ESW8Z5BZSm